{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T18:45:37Z","timestamp":1777056337182,"version":"3.51.4"},"reference-count":92,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004054","name":"King Abdulaziz University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Cancer is a devastating disease that takes the lives of millions of people globally every year. Precision cancer therapy is based on a patient\u2019s tumor histopathology, expression analyses, and\/or tumor RNA or DNA analysis. Only 2%\u201320% of patients with solid tumors benefit from genomics-based precision oncology. Therefore, functional diagnostics and patient-derived cancer models are needed for precision cancer therapy. In this review, we will summarize the potential use of conditional cell reprogramming (CR) and robotic high-throughput screening in precision cancer medicine. Briefly, the CR method includes the co-culturing of irradiated Swiss-3T3-J2 mouse fibroblast cells alongside digested primary non-pathogenic or pathogenic cells with the existence of Rho-associated serine\u2013threonine protein kinase inhibitor called Y-27632, creating an exterior culture environment, allowing the cells to have the ability to gain partial properties of stem cells. On the other hand, quantitative high-throughput screening (qHTS) assays screen thousands of compounds that use cells in a short period of time. The combination of both technologies has the potential to become a driving force for precision cancer therapy.<\/jats:p>","DOI":"10.3389\/fonc.2021.761986","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T20:52:25Z","timestamp":1634763145000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Conditionally Reprogrammed Cells and Robotic High-Throughput Screening for Precision Cancer Therapy"],"prefix":"10.3389","volume":"11","author":[{"given":"Faris","family":"Alkhilaiwi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33587","article-title":"The Ever-Increasing Importance of Cancer as a Leading Cause of Premature Death Worldwide","volume":"127","author":"Bray","year":"2021","journal-title":"Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajme.2011.01.002","article-title":"Development of Cancer Treatment Guidelines","volume":"47","author":"Kiel","year":"2011","journal-title":"Alexandria J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nature12624","article-title":"Tumour Heterogeneity and Cancer Cell Plasticity","volume":"501","author":"Meacham","year":"2013","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb1503104","article-title":"Precision Medicine \u2014 Personalized, Problematic, and Promising","volume":"372","author":"Jameson","year":"2015","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4389","article-title":"Functional Precision Cancer Medicine-Moving Beyond Pure Genomics","volume":"23","author":"Letai","year":"2017","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040938","article-title":"Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non\u2013Small-Cell Lung Cancer to Gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099314","article-title":"EGFR Mutations in Lung, Cancer: Correlation With Clinical Response to Gefitinib Therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nature09454","article-title":"Clinical Efficacy of a RAF Inhibitor Needs Broad Target Blockade in BRAF-Mutant Melanoma","volume":"467","author":"Bollag","year":"2010","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of Mutated, Activated BRAF in Metastatic Melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for Classical Hodgkin\u2019s Lymphoma After Failure of Both Autologous Stem-Cell Transplantation and Brentuximab Vedotin: A Multicentre, Multicohort, Single-Arm Phase 2 Trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine Molecular Profiling of Patients With Advanced Non-Small-Cell Lung Cancer: Results of a 1-Year Nationwide Programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.4165","article-title":"Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials","volume":"33","author":"Meric-Bernstam","year":"2015","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.87062","article-title":"Institutional Implementation of Clinical Tumor Profiling on an Unselected Cancer Population","volume":"1","author":"Sholl","year":"2016","journal-title":"JCI Insight"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.1660","article-title":"Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology","volume":"4","author":"Marquart","year":"2018","journal-title":"JAMA Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers6031769","article-title":"Drug Resistance in Cancer: An Overview","volume":"6","author":"Housman","year":"2014","journal-title":"Cancers"},{"key":"B19","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.tibtech.2019.12.021","article-title":"Enabling Technologies for Personalized and Precision Medicine","volume":"38","author":"Ho","year":"2020","journal-title":"Trends Biotechnol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41585-020-00389-2","article-title":"Patient-Derived Tumour Models for Personalized Therapeutics in Urological Cancers","volume":"18","author":"van de Merbel","year":"2021","journal-title":"Nat Rev Urol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nature15526","article-title":"Differential Responses to Lithium in Hyperexcitable Neurons From Patients With Bipolar Disorder","volume":"527","author":"Mertens","year":"2015","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad7653","article-title":"Pharmacological Reversal of a Pain Phenotype in iPSC-Derived Sensory Neurons and Patients With Inherited Erythromelalgia","volume":"8","author":"Cao","year":"2016","journal-title":"Sci Trans Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2576","article-title":"Identification of a Population of Blood Circulating Tumor Cells From Breast Cancer Patients That Initiates Metastasis in a Xenograft Assay","volume":"31","author":"Baccelli","year":"2013","journal-title":"Nat Biotechnol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/nm.3600","article-title":"Tumorigenicity and Genetic Profiling of Circulating Tumor Cells in Small-Cell Lung Cancer","volume":"20","author":"Hodgkinson","year":"2014","journal-title":"Nat Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005109","article-title":"The Identification and Characterization of Breast Cancer CTCs Competent for Brain Metastasis","volume":"5","author":"Zhang","year":"2013","journal-title":"Sci Trans Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/science.1253533","article-title":"Ex Vivo Culture of Circulating Breast Tumor Cells for Individualized Testing of Drug Susceptibility","volume":"345","author":"Yu","year":"2014","journal-title":"Science"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nrc4015","article-title":"Precision Medicine for Cancer With Next-Generation Functional Diagnostics","volume":"15","author":"Friedman","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.12.021","article-title":"Organoid Models of Human and Mouse Ductal Pancreatic Cancer","volume":"160","author":"Boj","year":"2015","journal-title":"Cell"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nature14415","article-title":"Sequential Cancer Mutations in Cultured Human Intestinal Stem Cells","volume":"521","author":"Drost","year":"2015","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3585","article-title":"Oncogenic Transformation of Diverse Gastrointestinal Tissues in Primary Organoid Culture","volume":"20","author":"Li","year":"2014","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-014-0428-9","article-title":"Metastatic Tumor Evolution and Organoid Modeling Implicate TGFBR2 as a Cancer Driver in Diffuse Gastric Cancer","volume":"15","author":"Nadauld","year":"2014","journal-title":"Genome Biol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.gde.2013.11.012","article-title":"Organoid Cultures for the Analysis of Cancer Phenotypes","volume":"24","author":"Sachs","year":"2014","journal-title":"Curr Opin Genet Dev"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.03.053","article-title":"Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients","volume":"161","author":"van de Wetering","year":"2015","journal-title":"Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.11.029","article-title":"Collective Invasion in Breast Cancer Requires a Conserved Basal Epithelial Program","volume":"155","author":"Cheung","year":"2013","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1242\/jcs.200543","article-title":"3D Cell Biology - The Expanding Frontier","volume":"130","author":"Ewald","year":"2017","journal-title":"J Cell Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3873","article-title":"Three-Dimensional Organotypic Culture: Experimental Models of Mammalian Biology and Disease","volume":"15","author":"Shamir","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-018-0662-9","article-title":"Organoid Technology and Applications in Cancer Research","volume":"11","author":"Xu","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw6985","article-title":"Cancer Modeling Meets Human Organoid Technology","volume":"364","author":"Tuveson","year":"2019","journal-title":"Science"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddy187","article-title":"Use and Application of 3D-Organoid Technology","volume":"27","author":"Artegiani","year":"2018","journal-title":"Hum Mol Genet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-1154","article-title":"Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine","volume":"7","author":"Pauli","year":"2017","journal-title":"Cancer Discov"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-04495-z","article-title":"Patient Derived Organoids to Model Rare Prostate Cancer Phenotypes","volume":"9","author":"Puca","year":"2018","journal-title":"Nat Commun"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0000000000000680","article-title":"Organoids for Replacement Therapy: Expectations, Limitations and Reality","volume":"24","author":"Xinaris","year":"2019","journal-title":"Curr Opin Organ Transplant"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-010-0540-6","article-title":"Patient-Derived Human Tumour Tissue Xenografts in Immunodeficient Mice: A Systematic Review","volume":"12","author":"Jin","year":"2010","journal-title":"Clin Trans Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2012.61","article-title":"Patient-Derived Tumour Xenografts as Models for Oncology Drug Development","volume":"9","author":"Tentler","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2013.92","article-title":"Patient-Derived Xenografts, the Cancer Stem Cell Paradigm, and Cancer Pathobiology in the 21st Century","volume":"93","author":"Williams","year":"2013","journal-title":"Lab Invest"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-021-01970-2","article-title":"Patient-Derived Tumor Models: A More Suitable Tool for Pre-Clinical Studies in Colorectal Cancer","volume":"40","author":"Rizzo","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2016.174","article-title":"Conditional Reprogramming and Long-Term Expansion of Normal and Tumor Cells From Human Biospecimens","volume":"12","author":"Liu","year":"2017","journal-title":"Nat Protoc"},{"key":"B48","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ajpath.2011.10.036","article-title":"ROCK Inhibitor and Feeder Cells Induce the Conditional Reprogramming of Epithelial Cells","volume":"180","author":"Liu","year":"2012","journal-title":"Am J Pathol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1213241109","article-title":"Conditionally Reprogrammed Cells Represent a Stem-Like State of Adult Epithelial Cells","volume":"109","author":"Suprynowicz","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"B50","doi-asserted-by":"publisher","first-page":"dmm031716","DOI":"10.1242\/dmm.031716","article-title":"Expanding Primary Cells From Mucoepidermoid and Other Salivary Gland Neoplasms for Genetic and Chemosensitivity Testing","volume":"11","author":"Alamri","year":"2018","journal-title":"Dis Models Mech"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13937","article-title":"Conditionally Reprogrammed Normal and Primary Tumor Prostate Epithelial Cells: A Novel Patient-Derived Cell Model for Studies of Human Prostate Cancer","volume":"8","author":"Timofeeva","year":"2017","journal-title":"Oncotarget"},{"key":"B52","first-page":"1","article-title":"Long-Term Expansion of Primary Equine Keratinocytes That Maintain the Ability to Differentiate Into Stratified Epidermis","volume-title":"Stem Cell Res Ther","author":"Alkhilaiwi","year":"2018"},{"key":"B53","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1152\/japplphysiol.00043.2018","article-title":"Development of a Polarized Pancreatic Ductular Cell Epithelium for Physiological Studies","volume":"125","author":"O\u2019Malley","year":"2018","journal-title":"J Appl Physiol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41389-019-0119-1","article-title":"Most Canine Ameloblastomas Harbor HRAS Mutations, Providing a Novel Large-Animal Model of RAS-Driven Cancer","volume":"8","author":"Saffari","year":"2019","journal-title":"Oncogenesis"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136851","article-title":"Ability to Generate Patient-Derived Breast Cancer Xenografts is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes","volume":"10","author":"McAuliffe","year":"2015","journal-title":"PloS One"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.04.019","article-title":"Comprehensive Drug Testing of Patient-Derived Conditionally Reprogrammed Cells From Castration-Resistant Prostate Cancer","volume":"71","author":"Saeed","year":"2017","journal-title":"Eur Urol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e662","DOI":"10.1016\/S1569-9056(18)31299-5","article-title":"High-Throughput Drug Screening Using Conditionally Reprogrammed Patient-Derived Cell Lines in Bladder Cancer","volume":"17","author":"Bostr\u00f6m","year":"2018","journal-title":"Eur Urol Suppl"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep17792","article-title":"Pseudo-Immortalization of Postnatal Cochlear Progenitor Cells Yields a Scalable Cell Line Capable of Transcriptionally Regulating Mature Hair Cell Genes","volume":"5","author":"Walters","year":"2015","journal-title":"Sci Rep"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-015-3551-8","article-title":"Developing In Vitro Models of Human Ductal Carcinoma in Situ From Primary Tissue Explants","volume":"153","author":"Brown","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203055","article-title":"Use of Reprogrammed Cells to Identify Therapy for Respiratory Papillomatosis","volume":"367","author":"Yuan","year":"2012","journal-title":"N Engl J Med"},{"key":"B61","first-page":"57","article-title":"In Vitro Culture of Long-Term Patient-Derived Conditionally Reprogrammed Cells From Lung Cancer and Application to Individual Chemotherapeutic Susceptibility Studies","author":"Zhangyan","year":"2017","journal-title":"Pharm Today"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.11.051","article-title":"Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care","volume":"21","author":"Kodack","year":"2017","journal-title":"Cell Rep"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100935","article-title":"Rapid Screening for Individualized Chemotherapy Optimization of Colorectal Cancer: A Novel Conditional Reprogramming Technology-Based Functional Diagnostic Assay","volume":"14","author":"Li","year":"2021","journal-title":"Trans Oncol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-11764-2","article-title":"A Multiplex Preclinical Model for Adenoid Cystic Carcinoma of the Salivary Gland Identifies Regorafenib as a Potential Therapeutic Drug","volume":"7","author":"Chen","year":"2017","journal-title":"Sci Rep"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0089-T","article-title":"In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer","volume":"13","author":"Hollevoet","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1016\/j.jamcollsurg.2018.08.213","article-title":"Conditional Reprogramming Cells Are Novel Tools for Drug Response Assay and the Development of Personalized Medicine in Luminal-B Breast Cancer","volume":"227","author":"Mimoto","year":"2018","journal-title":"J Am Coll Surg"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188584","article-title":"Cisplatin or LA-12 Enhance Killing Effects of TRAIL in Prostate Cancer Cells Through Bid-Dependent Stimulation of Mitochondrial Apoptotic Pathway But Not Caspase-10","volume":"12","author":"Blan\u00e1\u0159ov\u00e1","year":"2017","journal-title":"PloS One"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1126\/science.1254721","article-title":"Patient-Derived Models of Acquired Resistance can Identify Effective Drug Combinations for Cancer","volume":"346","author":"Crystal","year":"2014","journal-title":"Science"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-19-0191","article-title":"The Sustained Induction of C-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells","volume":"17","author":"Parasido","year":"2019","journal-title":"Mol Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.0c16262","article-title":"Magnetically Responsive Film Decorated With Microcilia for Robust and Controllable Manipulation of Droplets","volume":"13","author":"Chen","year":"2021","journal-title":"ACS Appl Mater Interfaces"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0604348103","article-title":"Quantitative High-Throughput Screening: A Titration-Based Approach That Efficiently Identifies Biological Activities in Large Chemical Libraries","volume":"103","author":"Inglese","year":"2006","journal-title":"Proc Natl Acad Sci"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/cnma.202000352","article-title":"Phototaxis Motion Behavior of a Self-Propelled Submarine-Like Water Droplet Robot in Oil Solvent","volume":"6","author":"Sun","year":"2020","journal-title":"ChemNanoMat"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1126\/science.1154619","article-title":"Transforming Environmental Health Protection","volume":"319","author":"Collins","year":"2008","journal-title":"Science"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2013.05.015","article-title":"The Tox21 Robotic Platform for the Assessment of Environmental Chemicals - From Vision to Reality","volume":"18","author":"Attene-Ramos","year":"2013","journal-title":"Drug Discov Today"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4578","article-title":"Mitigating Risk in Academic Preclinical Drug Discovery","volume":"14","author":"Dahlin","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1289\/ehp.1205784","article-title":"Improving the Human Hazard Characterization of Chemicals: A Tox21 Update","volume":"121","author":"Tice","year":"2013","journal-title":"Environ Health Perspect"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2914","article-title":"Phenotypic Screening of the ToxCast Chemical Library to Classify Toxic and Therapeutic Mechanisms","volume":"32","author":"Kleinstreuer","year":"2014","journal-title":"Nat Biotechnol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1015-1109a","article-title":"Prediction of Human Population Responses to Toxic Compounds by a Collaborative Competition","volume":"33","author":"Eduati","year":"2015","journal-title":"Nat Biotechnol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1289\/ehp.1408775","article-title":"Population-Based In Vitro Hazard and Concentration-Response Assessment of Chemicals: The 1000 Genomes High-Throughput Screening Study","volume":"123","author":"Abdo","year":"2015","journal-title":"Environ Health Perspect"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.pvr.2019.100181","article-title":"High-Throughput Screening Identifies Candidate Drugs for the Treatment of Recurrent Respiratory Papillomatosis","volume":"8","author":"Alkhilaiwi","year":"2019","journal-title":"Papillomavirus Res"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-17628-z","article-title":"Non-Malignant Epithelial Cells Preferentially Proliferate From Nasopharyngeal Carcinoma Biopsy Cultured Under Conditionally Reprogrammed Conditions","volume":"7","author":"Yu","year":"2017","journal-title":"Sci Rep"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14366","article-title":"Non-Malignant Respiratory Epithelial Cells Preferentially Proliferate From Resected non-Small Cell Lung Cancer Specimens Cultured Under Conditionally Reprogrammed Conditions","volume":"8","author":"Gao","year":"2017","journal-title":"Oncotarget"},{"key":"B83","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/ijc.31260","article-title":"Conditionally Reprogrammed Cells (CRC) Methodology Does Not Allow the In Vitro Expansion of Patient-Derived Primary and Metastatic Lung Cancer Cells","volume":"143","author":"Sette","year":"2018","journal-title":"Int J Cancer"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31383","article-title":"Expansion of Airway Basal Epithelial Cells From Primary Human non-Small Cell Lung Cancer Tumors","volume":"143","author":"Hynds","year":"2018","journal-title":"Int J Cancer"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-22427-1","article-title":"Patient-Derived Conditionally Reprogrammed Cells Maintain Intra-Tumor Genetic Heterogeneity","volume":"8","author":"Correa","year":"2018","journal-title":"Sci Rep"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep45617","article-title":"HPV Positive Neuroendocrine Cervical Cancer Cells are Dependent on Myc But Not E6\/E7 Viral Oncogenes","volume":"7","author":"Yuan","year":"2017","journal-title":"Sci Rep"},{"key":"B87","first-page":"4256","article-title":"Abstract 4256: Functional Analysis for Cancer Precision Medicine Using Patient-Derived 2D and 3D Cell Models","volume-title":"Cancer Res","author":"Liu","year":"2016"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201507-1414OC","article-title":"Rapid Expansion of Human Epithelial Stem Cells Suitable for Airway Tissue Engineering","volume":"194","author":"Butler","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23363","article-title":"Characterization of the Effects of Defined, Multidimensional Culture Conditions on Conditionally Reprogrammed Primary Human Prostate Cells","volume":"9","author":"Tricoli","year":"2018","journal-title":"Oncotarget"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ol.2020.11939","article-title":"Detection of Circulating Tumor Cells in Patients With Breast Cancer Using the Conditionally Reprogrammed Cell Culture Method and Reverse Transcription-PCR of Htert and Mage A1-6","volume":"20","author":"Jeong","year":"2020","journal-title":"Oncol Lett"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.12404","article-title":"Detection of Circulating Gastrointestinal Cancer Cells in Conditionally Reprogrammed Cell Culture","volume":"35","author":"Yang","year":"2021","journal-title":"In Vivo"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24050","article-title":"Predicting New Drug Indications for Prostate Cancer: The Integration of an in Silico Proteochemometric Network Pharmacology Platform With Patient-Derived Primary Prostate Cells","volume":"80","author":"Naeem","year":"2020","journal-title":"Prostate"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.761986\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T20:52:29Z","timestamp":1634763149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.761986\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,19]]},"references-count":92,"alternative-id":["10.3389\/fonc.2021.761986"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.761986","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,19]]},"article-number":"761986"}}